11/23，FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率，与辉瑞的 tafamidis 展开直接竞争，后者具有相同的作用机制，但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂，FDA的批准称该 ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...

Bath & Body Works (NYSE:BBWI – Free Report) had its target price increased by Deutsche Bank Aktiengesellschaft from $51.00 to ...

The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...